An Artemisia scoparia extract attenuates glucocorticoid-induced lipolysis in adipocytes.

Prescription glucocorticoid (GC) use is widespread across developed countries for the treatment of several inflammatory conditions. Elevated GCs are known to promote lipolysis and metabolic disorders. An extract of Artemisia scoparia (SCO) has been shown to reduce lipolysis and promote metabolic health but has not been investigated in the context of excess GCs. Our aim was to examine the effects of SCO on GC‐induced lipolysis.

[1]  K. Bohnert,et al.  A fat-promoting botanical extract from Artemisia scoparia exerts geroprotective effects on C. elegans lifespan and stress resistance. , 2022, The journals of gerontology. Series A, Biological sciences and medical sciences.

[2]  Allison J. Richard,et al.  Artemisia scoparia and Metabolic Health: Untapped Potential of an Ancient Remedy for Modern Use , 2022, Frontiers in Endocrinology.

[3]  Brett A. Collins,et al.  FGF1 and insulin control lipolysis by convergent pathways. , 2022, Cell metabolism.

[4]  J. Stephens,et al.  Artemisia scoparia promotes adipogenesis in the absence of adipogenic effectors , 2021, Obesity.

[5]  I. Raskin,et al.  Prenylated Coumaric Acids from Artemisia scoparia Beneficially Modulate Adipogenesis. , 2021, Journal of natural products.

[6]  T. Harris,et al.  Adipocyte lipolysis drives acute stress-induced insulin resistance , 2020, Scientific Reports.

[7]  Tenzin Dagpo,et al.  Exploring Therapeutic Targets to Reverse or Prevent the Transition from Metabolically Healthy to Unhealthy Obesity , 2020, Cells.

[8]  Alexander Yang,et al.  Adipocyte lipolysis: from molecular mechanisms of regulation to disease and therapeutics. , 2020, The Biochemical journal.

[9]  Joseph W. Jackson,et al.  One week of continuous corticosterone exposure impairs hepatic metabolic flexibility, promotes islet β-cell proliferation, and reduces physical activity in male C57BL/6 J mice , 2019, The Journal of Steroid Biochemistry and Molecular Biology.

[10]  H. Sørensen,et al.  Fifteen-year nationwide trends in systemic glucocorticoid drug use in Denmark. , 2019, European journal of endocrinology.

[11]  I. Raskin,et al.  Distinct Fractions of an Artemisia scoparia Extract Contain Compounds With Novel Adipogenic Bioactivity , 2019, Front. Nutr..

[12]  J. Rood,et al.  An ethanolic extract of Artemisia scoparia inhibits lipolysis in vivo and has antilipolytic effects on murine adipocytes in vitro. , 2018, American journal of physiology. Endocrinology and metabolism.

[13]  Nathan R. Qi,et al.  Glucocorticoid-Induced Metabolic Disturbances Are Exacerbated in Obese Male Mice , 2018, Endocrinology.

[14]  A. Pariente,et al.  Prevalence and prescription patterns of oral glucocorticoids in adults: a retrospective cross-sectional and cohort analysis in France , 2017, BMJ Open.

[15]  H. Sørensen,et al.  Systemic glucocorticoid use in Denmark: a population-based prevalence study , 2017, BMJ Open.

[16]  C. Diwoky,et al.  Pharmacological inhibition of adipose triglyceride lipase corrects high-fat diet-induced insulin resistance and hepatosteatosis in mice , 2017, Nature Communications.

[17]  G. Shulman,et al.  Mechanism for leptin’s acute insulin-independent effect to reverse diabetic ketoacidosis , 2017, The Journal of clinical investigation.

[18]  D. Langin,et al.  Adipocyte lipolysis and insulin resistance. , 2016, Biochimie.

[19]  I. Hochberg,et al.  Gene expression changes in subcutaneous adipose tissue due to Cushing's disease , 2015, Journal of molecular endocrinology.

[20]  B. Geng,et al.  Thiazolidinediones attenuate lipolysis and ameliorate dexamethasone-induced insulin resistance. , 2015, Metabolism: clinical and experimental.

[21]  T. Mikkelsen,et al.  Identification of nuclear hormone receptor pathways causing insulin resistance by transcriptional and epigenomic analysis , 2014, Nature Cell Biology.

[22]  R. MacPherson,et al.  Evidence for fatty acids mediating CL 316,243-induced reductions in blood glucose in mice. , 2014, American journal of physiology. Endocrinology and metabolism.

[23]  J. Alvarez‐Leite,et al.  Low-Grade Inflammation, Obesity, and Diabetes , 2014, Current Obesity Reports.

[24]  D. Ribnicky,et al.  Artemisia extracts activate PPARγ, promote adipogenesis, and enhance insulin sensitivity in adipose tissue of obese mice. , 2014 .

[25]  D. Ribnicky,et al.  Artemisia scoparia Enhances Adipocyte Development and Endocrine Function In Vitro and Enhances Insulin Action In Vivo , 2014, PloS one.

[26]  W. Johnson,et al.  Artemisia scoparia extract attenuates non-alcoholic fatty liver disease in diet-induced obesity mice by enhancing hepatic insulin and AMPK signaling independently of FGF21 pathway. , 2013, Metabolism: clinical and experimental.

[27]  C. Deal,et al.  Prevalence of oral glucocorticoid usage in the United States: A general population perspective , 2013, Arthritis care & research.

[28]  S. Collins,et al.  β-Adrenoceptor Signaling Networks in Adipocytes for Recruiting Stored Fat and Energy Expenditure , 2011, Front. Endocrin..

[29]  I. Petersen,et al.  Prevalence of long-term oral glucocorticoid prescriptions in the UK over the past 20 years. , 2011, Rheumatology.

[30]  J. Graff,et al.  Thiazolidinediones regulate adipose lineage dynamics. , 2011, Cell metabolism.

[31]  Terence P. Speed,et al.  Genome-Wide Analysis of Glucocorticoid Receptor Binding Regions in Adipocytes Reveal Gene Network Involved in Triglyceride Homeostasis , 2010, PloS one.

[32]  P. Strålfors,et al.  Differential regulation of adipocyte PDE3B in distinct membrane compartments by insulin and the beta3-adrenergic receptor agonist CL316243: effects of caveolin-1 knockdown on formation/maintenance of macromolecular signalling complexes. , 2009, The Biochemical journal.

[33]  Guoheng Xu,et al.  Direct effect of glucocorticoids on lipolysis in adipocytes. , 2009, Molecular endocrinology.

[34]  C. Rosen.  The rosiglitazone story--lessons from an FDA Advisory Committee meeting. , 2007, The New England journal of medicine.

[35]  S. Nissen,et al.  Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.

[36]  P. Arner,et al.  NF-kappaB is important for TNF-alpha-induced lipolysis in human adipocytes. , 2007, Journal of lipid research.

[37]  F. Sundler,et al.  Alterations in regulation of energy homeostasis in cyclic nucleotide phosphodiesterase 3B-null mice. , 2006, The Journal of clinical investigation.

[38]  E. Lander,et al.  Reactive oxygen species have a causal role in multiple forms of insulin resistance , 2006, Nature.

[39]  J. Cidlowski,et al.  Antiinflammatory action of glucocorticoids--new mechanisms for old drugs. , 2005, The New England journal of medicine.

[40]  J. Jessurun,et al.  Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. , 2005, The Journal of clinical investigation.

[41]  M. Conti,et al.  The Oligomerization State Determines Regulatory Properties and Inhibitor Sensitivity of Type 4 cAMP-specific Phosphodiesterases* , 2004, Journal of Biological Chemistry.

[42]  J. Jameson,et al.  A dominant negative PPARγ mutant shows altered cofactor recruitment and inhibits adipogenesis in 3T3-L1 cells , 2003, Diabetologia.

[43]  V. Manganiello,et al.  Tumor necrosis factor-alpha stimulates lipolysis in differentiated human adipocytes through activation of extracellular signal-related kinase and elevation of intracellular cAMP. , 2002, Diabetes.

[44]  L. Witters.  The blooming of the French lilac. , 2001, The Journal of clinical investigation.

[45]  J. Mei,et al.  Down-regulation of cyclic-nucleotide phosphodiesterase 3B in 3T3-L1 adipocytes induced by tumour necrosis factor alpha and cAMP. , 2000, The Biochemical journal.

[46]  D. Matthews,et al.  Systemic resistance to the antilipolytic effect of insulin in black and white women with visceral obesity. , 1999, American journal of physiology. Endocrinology and metabolism.

[47]  W Ogawa,et al.  Insulin-Induced Phosphorylation and Activation of Cyclic Nucleotide Phosphodiesterase 3B by the Serine-Threonine Kinase Akt , 1999, Molecular and Cellular Biology.

[48]  G. Boden.  Role of Fatty Acids in the Pathogenesis of Insulin Resistance and NIDDM , 1997, Diabetes.

[49]  S. Rössner,et al.  Effects of weight reduction on the regulation of lipolysis in adipocytes of women with upper-body obesity. , 1995, Clinical science.

[50]  A. Brasier,et al.  Tumor necrosis factor increases the rate of lipolysis in primary cultures of adipocytes without altering levels of hormone-sensitive lipase. , 1994, Endocrinology.

[51]  R. Bone,et al.  Role of tumor necrosis factor-α in disease states and inflammation , 1993 .

[52]  M. Jensen,et al.  Influence of body fat distribution on free fatty acid metabolism in obesity. , 1989, The Journal of clinical investigation.

[53]  L. Poellinger,et al.  Regulation of glucocorticoid receptor expression: evidence for transcriptional and posttranslational mechanisms. , 1988, Molecular endocrinology.

[54]  J. Stevens,et al.  Insulin resistance in adipocytes from fed and fasted obese rats: Dissociation of two insulin actions , 1981, Molecular and Cellular Biochemistry.

[55]  T. Hawke,et al.  Adipogenic and lipolytic effects of chronic glucocorticoid exposure. , 2011, American journal of physiology. Cell physiology.

[56]  F. Pi-Sunyer,et al.  Impaired insulin action in subcutaneous adipocytes from women with visceral obesity. , 2001, American journal of physiology. Endocrinology and metabolism.